Status:
SUSPENDED
68Ga-PSMA PET/CT in Prostate Cancer
Lead Sponsor:
University of Saskatchewan
Conditions:
Prostate Cancer
Eligibility:
MALE
18-100 years
Phase:
PHASE3
Brief Summary
This is a single-center, multi-arm, open-label, phase III trial in up to 500 patients with biopsy-proven prostate cancer. Participants will receive regular standard of clinical care. The only study-s...
Eligibility Criteria
Inclusion
- Male sex
- Age 18 years or older
- Previously diagnosed with prostate cancer, under referring physician's care
- ECOG performance status 0 - 3, inclusive
- Able to understand and provide written informed consent
- Able to tolerate the physical/logistical requirements of a PET/CT scan including lying supine (or prone) for up to 40 minutes and tolerating intravenous cannulation for injection
Exclusion
- Patients who are medically unstable (e.g. acute cardiac or respiratory distress or hypotensive)
- Patients who exceed the safe weight limit of the PET/CT bed (usually approximately 400 lbs.) or who cannot fit through the PET/CT bore (usually approximately 70 cm diameter)
- Patients with unmanageable claustrophobia
Key Trial Info
Start Date :
December 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04684628
Start Date
December 9 2020
End Date
December 1 2025
Last Update
May 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal University Hospital
Saskatoon, Saskatchewan, Canada, S7N 0W8